Sun Pharmaceutical Buropion Tablets Recall: Failed Dissolution Specifications
Sun Pharmaceutical recalls 200mg bupropion extended-release tablets due to failed dissolution specifications. This may affect product effectiveness. Consumers should contact Sun for details.
Lower-risk recall
Failed Dissolution Specifications
Contact the company
What happened, in plain English
Sun Pharmaceutical is recalling 200 mg bupropion hydrochloride extended-release tablets because they failed dissolution specifications. This could mean the medication doesn't work as intended. Read more at govinfonow.com/recall/32938-sun-pharmaceutical-buropion-tablets-recall-failed-dissolution-specifications.
Source Summary by GovInfoNow · govinfonow.com/recall/32938-sun-pharmaceutical-buropion-tablets-recall-failed-dissolution-specifications · Updated August 17, 2026 · FDA enforcement record: FDA #D-0137-2024
Cite this page
“Sun Pharmaceutical Buropion Tablets Recall: Failed Dissolution Specifications.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/32938-sun-pharmaceutical-buropion-tablets-recall-failed-dissolution-specifications. Based on FDA recall #D-0137-2024 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0137-2024%22&limit=1).
Why it’s dangerous
The tablets failed dissolution specifications, meaning they may not release the medication properly in the body. This could lead to the medication not working as intended. The risk is low because the issue affects product effectiveness, not safety.
Who’s affected
People who have the 200 mg bupropion extended-release tablets (NDC 47335-738-86) from Sun Pharmaceutical. Those with mental health conditions requiring this medication are most at risk.
How to tell if you have this one
Check for the 200 mg bupropion extended-release tablets (NDC 47335-738-86) with lot number HAD0630A, expiring 1/2024. The product was distributed by Sun Pharmaceutical.
- Brand
Sun Pharmaceutical- Category
Drug
What to do — step by step
Contact Sun for Details
Reach out to Sun Pharmaceutical for specific instructions on handling the recalled product.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 7 months after the firm started it.
- Firm started the recall
- FDA classified it Class III
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Other Sun Pharmaceutical recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0137-2024 (November 22, 2023) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0137-2024 to see it in context.
- Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.